Mounjaro vs Ozempic Price: the Comparison That Needs More Context

First: Ozempic isn't licensed for weight loss in the UK

This is the part of the comparison that tends to get buried. Ozempic contains semaglutide and is approved by the MHRA for type 2 diabetes management — not for weight loss. The semaglutide product licensed for weight management is Wegovy, which contains the same active ingredient at a higher dose and under a separate licence. Prescribing Ozempic for weight loss would be off-label, and a responsible prescriber won't do it simply because it appears cheaper. As the MHRA has stated clearly in its guidance on GLP-1 medicines for weight loss, these are not interchangeable products and should not be used for quick or cosmetic weight loss outside appropriate clinical pathways. So if you're researching Ozempic as a budget route to weight-loss treatment, that route doesn't exist legally or clinically. The real decision is between Mounjaro and Wegovy, you can read a factual breakdown of how their UK private prices compare separately.

That said, the question is understandable. The two brand names appear together constantly online, and if you want to understand how Mounjaro and Ozempic compare on cost, prices attached to Ozempic circulate freely on forums and social media, though the comparisons are rarely like-for-like.

How private pricing for weight-loss medicines actually works in the UK

Private weight-loss treatment in the UK is priced per pen or per month, and the figure varies with dose and provider. Eli Lilly raised the UK list price for Mounjaro from 1 September 2025 (the highest-dose pen's list price moved from around £122 to around £330) and typical private prices since then have ranged roughly £149 to £375 per month depending on dose and where you go, as widely reported at the time. Wegovy prices sit in a broadly similar range at equivalent doses. These aren't fixed: a 2.5mg starter pen costs considerably less than a 15mg maintenance pen, and what you pay at month three differs from month one.

What those headline numbers often leave out matters. Some providers charge separately for the consultation, the prescription, the delivery, and follow-up clinical support. Others bundle some but not all. A price that looks lower per pen can end up higher once you add those elements, or it can mean clinical oversight is thinner than it should be for a prescription medicine. Before you compare figures, it's worth asking what each one actually covers. A closer look at the Wegovy and Mounjaro price structures unpacks this in more detail.

What a genuinely all-inclusive private price looks like

At nume, one price covers the consultation, the prescription, the treatment, delivery and aftercare. We don't split these out, and we don't add fees between doses. Every repeat order goes through a fresh clinical review before it's approved, not as a formality, but because a prescriber should look at how treatment is going before extending it. If you order before 12pm on a working day and your consultation is approved, your treatment leaves our GPhC-registered pharmacy the same day and arrives with DPD the next working day, tracked, in plain packaging.

We're not the cheapest option in this market, and that's a deliberate choice. Running a same-day prescriber review, a proper identity and weight verification process, and genuine 7-day aftercare costs more than a basic order-and-ship model. Some people find that gap easy to weigh up; others want time to think about it. Either way, the right starting point is a free consultation, the kind that tells you what you're actually eligible for, not just what's available to order. Our clinical team is there to answer questions before you decide. You can also read about whether Ozempic is actually cheaper than Mounjaro in a dedicated breakdown, or explore the cost comparison from a different angle if you want the full picture before making a decision.

Why 'cheapest' is the wrong test for a prescription medicine

The MHRA seized around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million in 2025, including the first UK raid on a site producing counterfeit tirzepatide pens, in Northampton, in October that year. Fake pens have caused real harm, including hospitalisations. The common thread in those cases is price: listings that look significantly cheaper than the regulated market, often on social media, often with no verifiable clinical process behind them.

For a prescription medicine, the cheapest listing answers the wrong question entirely. What you're actually assessing is whether the supply chain is legitimate, whether a qualified clinician has reviewed your health before you inject, and whether there's someone to call if something doesn't feel right. You can verify any online pharmacy on the GPhC register; our premises registration number is 9012878. Suspect a counterfeit or a seller offering these medicines without a prescription? Report it at the MHRA's Yellow Card service. The right question isn't which pen costs least, it's which service gives you confidence that what arrives is genuine, prescribed appropriately, and supported properly. If you're ready to find out what you're eligible for, speak to our prescribers through a free consultation.